From Molecules to Novel Medicines that Make a Difference

These are exciting times for all of us at Otsuka. In addition to the many promising molecules we are currently investigating, we have numerous products at various stages of the clinical trial process. We take a holistic approach to contributing to people’s health and well-being. Our goal is to help develop treatment options and solutions to improve health. This is why we passionately embrace the opportunity to create ground-breaking products. New compounds discovered at research institutes are advanced to our clinical development institutes centered in the US, Europe, Japan and other Asian counties. We persevere, whatever the magnitude of the challenge, as we are committed to improving the health of people, worldwide. When it comes to research and development, we have always taken the long term view, always looking for solutions to problems, however long it takes.

Global Research Principles:

  • Embrace the challenge of continuously creating highly original pharmaceuticals which put patients first
  • Nurture unique pharmaceutical projects through Otsuka’s global satellite R&D systems
  • Leverage global research resources via our institutes in Japan, the US, China and the UK
  • Discover new pharmaceuticals related to the central nervous system, in oncology, and in other areas where medical needs remain underserved
  • With strong confidence in these research principles, Otsuka will continue to take on the challenge of creating truly unconventional solutions.



Below is a small selection of investigational compounds that are currently in various stages of development.
  • Brexpiprazole. For the treatment of agitation in Alzheimer’s disease; treatment of post-traumatic stress disorder (PTSD)
  • Delamanid. Treatment for multidrug-resistant tuberculosis


Research Vacancies


Otsuka Pipeline Graphic

Recent U.S. Clinical Milestones

  • 1996

    FDA approves BreathTek® UBT for H. pylori Kit for adults

  • 1999

    FDA approves PLETAL® (cilostazol)

  • 2002

    FDA approves ABILIFY® (aripiprazole), co-promoted with Bristol-Myers Squibb.

  • 2006

    FDA approves Sprycel® (dasatinib) - Bristol-Myers Squibb (BMS)

  • 2008

    Otsuka acquires IV BUSULFEX® (busulfan) from PDL BioPharma, Inc.

  • 2009

    FDA approves SAMSCA® (tolvaptan) 

  • 2013

    FDA approves ABILIFY MAINTENA® (aripiprazole) 

  • 2014

    Otsuka acquires rights from Eisai Inc. to develop and market DACOGEN® (decitabine) in the US, Canada and Japan.

  • 2015

    FDA approves REXULTI® (brexpiprazole) 

  • 2018

    FDA approves JYNARQUE® (tolvaptan) 


We Work Collaboratively

At Otsuka, we believe in collaborations to accelerate our understanding of diseases and the subsequent development of medicines and solutions to help people towards better health. We collaborate with other companies, such as affiliates Avanir and Astex, and with Lundbeck and GW Pharmaceuticals, Inc., with whom we have formed alliances because their skills complement those of Otsuka (see U.S. Affiliates and Alliances in Discover Otsuka).

With Harvard University

In addition, in keeping with our commitment to developing novel therapeutics and precision medicine in the CNS space, Otsuka has started a collaboration with Q-State Biosciences, a company founded by two Harvard University professors which has developed proprietary optical and stem cell technologies to visualize disease pathologies and drug effects in electrically active cells.

With Princeton University

By leveraging DNA samples and clinical data from retrospective clinical trials, Otsuka in collaboration with Dr. John Storey's laboratory at the Lewis-Sigler Institute for Genomics, Princeton University, has begun performing large-scale pharmacogenomics studies to discover significant molecular associations with placebo/drug response in schizophrenia, bipolar depression and major depressive disorder patients enrolled in Otsuka's CNS trials.

With George Washington University

Otsuka in collaboration with George Washington University is undertaking a big data and machine learning approach to mine structured and un-structured data in the form of Electronic Health Records (EHR) of large CNS patient cohorts enrolled in the Veterans Affairs healthcare system. The aims of this collaboration are to understand treatment pathways and their outcomes, early signs/diagnosis, markers of relapse and to develop new efficacy measures from EHRs.


Otsuka has been committed for more than 3 decades to developing novel drugs for neurological conditions.